Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08GVP
|
|||
| Drug Name |
ADX-914
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Atopic dermatitis [ICD-11: EA80; ICD-10: L20] | Phase 2 | [1] | |
| Company |
Horizon Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 7 receptor alpha (IL7R) | Target Info | Antagonist | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| FoxO signaling pathway | ||||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| Primary immunodeficiency | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| IL4 Signaling Pathway | ||||
| TNFalpha Signaling Pathway | ||||
| Leptin Signaling Pathway | ||||
| Reactome | Interleukin-7 signaling | |||
| WikiPathways | Apoptosis-related network due to altered Notch3 in ovarian cancer | |||
| Interleukin-7 signaling | ||||
| TSLP Signaling Pathway | ||||
| IL-7 Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05509023) A Randomized, Double-Blind, Placebo-Controlled Phase 2a Proof-of-Concept Study Evaluating the Safety and Efficacy of ADX-914 in Subjects With Moderate to Severe Atopic Dermatitis. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Q32bio | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.